Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.62 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 3/20 | 0.39 |
| ▸ | DNM1 | Q05193 | 8/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
| ▸ | GHSR | Q92847 | 1/20 | 0.37 |
| ▸ | NT5E | P21589 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA4 | P22748 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Octadecylamine SCHEMBL9548499 | 1.00 | TDP1 (0.62) | TDP1S1PR3CA2DNM1ALDH1A1 | |
| SCHEMBL21990592 | 0.84 | TDP1 (0.60) | TDP1S1PR3CA2CA12CA1 | |
| Tetrabuthylammonium SCHEMBL7765608 | 0.84 | TDP1 (0.64) | TDP1S1PR3CA2ALDH1A1TSHR | |
| SCHEMBL11786735 | 0.81 | MCHR1 (0.49) | TDP1S1PR3CA2DNM1ALDH1A1 | |
| Octadecylamine SCHEMBL28750204 | 0.81 | MCHR1 (0.49) | TDP1S1PR3CA2DNM1ALDH1A1 | |
| Hexadecylamine SCHEMBL9058486 | 0.81 | MCHR1 (0.49) | TDP1S1PR3CA2DNM1ALDH1A1 | |
| SCHEMBL6910871 | 0.81 | MCHR1 (0.49) | TDP1S1PR3CA2DNM1ALDH1A1 | |
| Decylamine SCHEMBL29134163 | 0.81 | MCHR1 (0.49) | TDP1S1PR3CA2DNM1ALDH1A1 | |
| Dodecylamine SCHEMBL28101896 | 0.81 | MCHR1 (0.49) | TDP1S1PR3CA2DNM1ALDH1A1 | |
| Monoethanolamine SCHEMBL11126568 | 0.81 | TDP1 (0.75) | TDP1CA2ALDH1A1TSHRNT5E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11459410-B2 | High-purity amphipathic arylsulfonic acid amine salt vinyl monomer and copolymer thereof | TOSOH FINECHEM CORPORATION (JP) | 2022-10-04 | — | — | US | disclosed |
| CN-110997631-B | High purity amphiphilic arylsulfonic acid amine salt vinyl monomers and (co) polymers thereof | 东曹精细化工株式会社 | 2022-07-15 | — | — | CN | disclosed |
| EP-3666753-A1 | HIGH-PURITY AMPHIPATHIC ARYLSULFONIC ACID AMINE SALT VINYL MONOMER AND COPOLYMER THEREOF | Tosoh Finechem Corporation (JP) | 2020-06-17 | — | — | EP | disclosed |
| US-20200172643-A1 | HIGH-PURITY AMPHIPATHIC ARYLSULFONIC ACID AMINE SALT VINYL MONOMER AND COPOLYMER THEREOF | TOSOH FINECHEM CORPORATION (JP) | 2020-06-04 | — | — | US | disclosed |
| CN-110997631-A | High purity amphiphilic arylsulfonic acid amine salt vinyl monomers and (co) polymers thereof | 东曹精细化工株式会社 | 2020-04-10 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11459410-B2 | High-purity amphipathic arylsulfonic acid amine salt vinyl monomer and copolymer thereof | SLC7A1, ARSA, STS | TDP1 3230/4885S1PR3 676/4885CA2 2972/4885 |
| US-20200172643-A1 | HIGH-PURITY AMPHIPATHIC ARYLSULFONIC ACID AMINE SALT VINYL MONOMER AND COPOLYMER THEREOF | SLC7A1, ARSA, STS | TDP1 3230/4885S1PR3 676/4885CA2 2972/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.